
NYSE:TMO
11 expert ratings on Thermo Fisher Scientific (TMO) in the last 12 months: 8 Buy, 2 Hold, 1 Sell. Latest rating: HOLD by Christine Poole on Nov 10, 2026.
Boosted guidance, buying back shares. US company, but global (about 50/50). Trades ~15x PE for ~10% growth. Not your best way to build wealth quickly, yet a steady eddy. Pretty fully priced, but reasonable value.
Drawdown due to healthcare, not to this name specifically. High quality. Won't lose long term. He'd sell some puts.
"The AMZN of life sciences." Massive, diversified giant. Pressure from biotech funding crunch, high interest rates, and both softness and a new procurement bidding system in China. This has all dampened pricing and margins.
Likes its good, recurring revenue stream at 50% or even more. Global scale, dominant market positions, unmatched supply chains, significant moats against small competitors. Yield is 0.34%.
The biggest company in life sciences. Are focusing on clinical research services. TMO suffered a bad decline early this year, but has strongly recovered since then. Is up more than 50% since mid-June lows. They last reported a top and bottom line beat and raised full-year guidance. Tough areas like academia and China are growing again. Are partnering with openAI to speed up developing new tools and technology and drug development. Acquisitions are working.
Both are in the same space of life sciences products, though DHR trades at a slightly higher valuation.
Owns and likes this name. Picks and shovels to the healthcare industry. Can help a company take a drug from development to clinical trials to production. Clients include healthcare, pharma, government, and labs. Growth slowed a bit after Covid, in China, and with higher interest rates. CEO still expects industry to grow 5-7%. Demographics makes healthcare a long-term growth story.
Any small wrinkle imposed by Trump withdrawing funding to universities is offset by its geographic and client diversification.
Starting to see a bit of turnaround in the healthcare space. She bought in March, and again in June; trimmed in October, taking some profits. Pharma and biotech spending starting to pick up, especially in cell and gene therapy. OpenAI partnership is major step forward. Cashflow remains very healthy. Ranks 8/10, still sees double-digit upside.
Thermo Fisher Scientific is a American stock, trading under the symbol TMO (previously TMO-N on Stockchase) on the New York Stock Exchange (TMO). It is usually referred to as NYSE:TMO or TMO
11 expert ratings on Thermo Fisher Scientific (TMO) in the last 12 months: 8 Buy, 2 Hold, 1 Sell. Latest rating: HOLD by Christine Poole on Nov 10, 2026. Read the latest stock experts' ratings for Thermo Fisher Scientific.
Thermo Fisher Scientific was recommended as a Top Pick by Christine Poole on 2026-11-10. Read the latest stock experts ratings for Thermo Fisher Scientific.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Thermo Fisher Scientific.
Thermo Fisher Scientific is followed by 187 investors on Stockchase and is a trending stock that is worth watching.
On 2026-11-20, Thermo Fisher Scientific (TMO) stock closed at a price of $669.54.
Picks and shovels for the healthcare industry. Grows in mid-high single-digit range. Very good operators and acquirers. Multiple's expanded, partly due to rotation from tech to healthcare. Keep holding for the long term.